Skip to main content

Table 2 Overall responses

From: A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer

 

Number

Percentage (%)

Assessable patients

54

100

Overall response

18

33.3

CR

1

1.9

PR

17

31.5

SD

27

50.0

PD

9

16.7

DCR (CR + PR + SD)

45

83.3

  1. Abbreviations: CR complete response, PR partial response, SD stable disease, PD progressive disease, DCR disease control rate
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us